Anti-SAFB (aa 111-200) polyclonal antibody

Name: Anti-SAFB (aa 111-200) polyclonal antibody
SKU: DPAB-DC2776
Rating: 5 (1 reviews)

Mouse anti-Human SAFB (aa 111-200) polyclonal antibody for WB, ELISA

COA

SDS

Datasheet

Summary

Specifications

Species Reactivity

Human

Immunogen

SAFB (NP_002958, 111 a.a. ~ 200 a.a) partial recombinant protein with GST tag. The sequence is DGQEDVETSLENLQDIDIMDISVLDEAEIDNGSVADCVEDDDADNLQESLSDSRELVEGE MKELPEQLQEHAIEDKETINNLDTSSSDFT

Conjugate

Unconjugated

Target

Alternative Names

SAFB; scaffold attachment factor B; HAP; HET; SAFB1; SAF-B1; scaffold attachment factor B1; SAF-B; SAB-B1; HSP27 ERE-TATA-binding protein; Hsp27 ERE-TATA binding protein; glutathione S-transferase fusion protein; HSP27 estrogen response element-TATA box-b

Entrez Gene ID

6294

UniProt ID

Q15424

Product Background

Antigen Description

This gene encodes a DNA-binding protein which has high specificity for scaffold or matrix attachment region DNA elements (S/MAR DNA). This protein is thought to be involved in attaching the base of chromatin loops to the nuclear matrix but there is conflicting evidence as to whether this protein is a component of chromatin or a nuclear matrix protein. Scaffold attachment factors are a specific subset of nuclear matrix proteins (NMP) that specifically bind to S/MAR. The encoded protein is thought to serve as a molecular base to assemble a transcriptosome complex in the vicinity of actively transcribed genes. It is involved in the regulation of heat shock protein 27 transcription, can act as an estrogen receptor co-repressor and is a candidate for breast tumorigenesis. This gene is arranged head-to-head with a similar gene whose product has the same functions. Multiple transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2011]

Citations

Have you cited DPAB-DC2776 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Quantitative Proteomic Identification of the BRCA1 Ubiquitination Substrates

JOURNAL OF PROTEOME RESEARCH

Authors: Song, Meihua; Hakala, Kevin; Weintraub, Susan T.; Shiio, Yuzuru

Abstract

Mutation of the BRCA1 tumor suppressor gene predisposes women to hereditary breast and ovarian cancers. BRCA1 forms a heterodimer with BARD I. The BRCA1/BARD1 heterodimer has ubiquitin ligase activity, considered to play crucial roles in tumor suppression and DNA damage response. Nevertheless, relevant BRCA1 substrates are poorly defined. We have developed a new approach to systematically identify the substrates of ubiquitin ligases by identifying proteins that display an enhanced incorporation of His-tagged ubiquitin upon ligase coexpression; using this method, we identified several candidate substrates for BRCA1. These include scaffold attachment factor B2 (SAFB2) and Tel2 as well as BARD1. BRCA1 was found to enhance SAFB protein expression and induce Tel2 nuclear translocation. Identification of the ubiquitination substrates has been a major obstacle to understanding the functions of ubiquitin ligases. The quantitative proteomics approach we devised for the identification of BRCA1 substrates will facilitate the identification of ubiquitin ligase-substrate pairs.

Monoclonal secondary reagents do not outperform polyclonal secondary reagents for detection ofanti-HLA IgGusing single antigen flow beads assays

HLA

Authors: Bonnet, Marie; Visentin, Jonathan; Caillat-Zucman, Sophie; Jollet, Isabelle; Taupin, Jean-Luc

Abstract

Luminex single antigen flow beads (SAFB) assays are used to monitor anti-HLA antibodies, which are associated with allograft loss. The primary antibody binding level is evaluated by the mean fluorescence intensity (MFI) provided by the tracing secondary antibody. The aim of this study was to compare the MFI obtained with two secondary antibodies and to evaluate their sensitivity to detect newly developed de novo anti-HLA donor-specific antibodies (dnDSA). A total of 23 and 46 different sera from 20 HLA-sensitized kidney transplant recipients were tested with class I and II SAFB, respectively, as well as sera from 17 patients with dnDSA. The conventional secondary antibody (IgHPolyFab) was the phycoerythrin (PE)-conjugated goat anti-human IgG constant heavy chain (HC)-binding polyclonal-F(ab')2. The alternate secondary antibody was a PE-conjugated anti-human IgG Fc-specific monoclonal IgG (FcMonoIgG). MFI of negative control sera were drastically lower with the FcMonoIgG than with IgHPolyFab, requesting a unique positivity threshold to be defined for each secondary antibody. MFI obtained with positive control sera were also lower with FcMonoIgG. In kidney transplant recipient's sera, the number of antigenic specificities detected by each secondary antibody was comparable, for dnDSA as well as for nonDSA. In conclusion, decision thresholds must be refined when changing the secondary tracing reagent in SAFB assays. FcMonoIgG did not demonstrate any superiority over IgHPolyFab for monitoring HLA antibodies.